Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- David Hsieh
- Target Recruit Count
- 35
- Registration Number
- NCT03519997
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
News
No news found